13 assets in Uterine Corpus Endometrial Carcinoma

Therapeutic assets addressing Uterine Corpus Endometrial Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cyclophosphamide Uterine Corpus Endometrial Carcinoma	Mayo Clinic	P1/2	CCC (48)
Pembrolizumab Uterine Corpus Endometrial Carcinoma	Mayo Clinic	P1/2	CCC (48)
Sargramostim Uterine Corpus Endometrial Carcinoma	Mayo Clinic	P1/2	CCC (48)
Carboplatin Uterine Corpus Endometrial Carcinoma	City of Hope Medical Center	P1	CC (47)
Adriamycin Uterine Corpus Endometrial Carcinoma	City of Hope Medical Center	P1	CC (43)
Capivasertib Uterine Corpus Endometrial Carcinoma	M.D. Anderson Cancer Center	P1	CC (43)
Ceralasertib Uterine Corpus Endometrial Carcinoma	National Cancer Institute (NCI)	P1	CC (43)
Cis-Diamminedichloroplatinum Ii Uterine Corpus Endometrial Carcinoma	City of Hope Medical Center	P1	CC (43)
Cobimetinib Uterine Corpus Endometrial Carcinoma	National Cancer Institute (NCI)	P1	CC (43)
Olaparib Uterine Corpus Endometrial Carcinoma	M.D. Anderson Cancer Center	P1	CC (43)
Pelcitoclax Uterine Corpus Endometrial Carcinoma	National Cancer Institute (NCI)	P1	CC (43)
Trastuzumab Deruxtecan Uterine Corpus Endometrial Carcinoma	National Cancer Institute (NCI)	P1	CC (43)
Vistusertib Uterine Corpus Endometrial Carcinoma	M.D. Anderson Cancer Center	P1	CC (43)